TY - JOUR
T1 - Water and electrolyte disorders at long-term post-treatment follow-up in paediatric patients with suprasellar tumours include unexpected persistent cerebral salt-wasting syndrome
AU - González Briceño, Laura
AU - Grill, Jacques
AU - Bourdeaut, Franck
AU - Doz, François
AU - Beltrand, Jacques
AU - Benabbad, Imane
AU - Brugières, Laurence
AU - Dufour, Christelle
AU - Valteau-Couanet, Dominique
AU - Guerrini-Rousseau, Léa
AU - Aerts, Isabelle
AU - Orbach, Daniel
AU - Alapetite, Claire
AU - Samara-Boustani, Dinane
AU - Pinto, Graziella
AU - Simon, Albane
AU - Touraine, Philippe
AU - Sainte-Rose, Christian
AU - Zerah, Michel
AU - Puget, Stéphanie
AU - Elie, Caroline
AU - Polak, Michel
N1 - Publisher Copyright:
© 2014 S. Karger AG, Basel.
PY - 2014/1/21
Y1 - 2014/1/21
N2 - Background: Patients with brain tumours have a high risk of water and electrolyte disorders (WED). Postsurgery diabetes insipidus (DI) may be transient or permanent, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt-wasting syndrome (CSWS) are usually transient. Methods: Retrospective study, including patients with suprasellar tumours, treated at Hôpital Necker, Institut Gustave-Roussy or Institut Curie, in Île-de-France, between 2007 and 2011. WED were noted if they persisted >1 month after surgery. Results: 159 patients were included, 54.1% girls, 43.9% boys. Tumour types were: glioma (43.4%), craniopharyngioma (43.4%), germinoma (11.3%), others (1.9%). Age at diagnosis was 7.1 ± 4.6 years. The median time from end of treatment was 1.9 (0-7.8) years. DI was the most frequent disorder after tumour treatment (50.3%) and was significantly associated with surgery (p < 0.001). Persistent CSWS was present in 3.6%, persistent SIADH in 1.3%. Two cases of hypernatraemia were due to adipsia. Thyrotropin deficiency after treatment was noted in 68.9% of patients tested, adrenocorticotropin deficiency in 66.2%. Conclusions: Patients with suprasellar tumours have a high incidence of long-term WED, mainly DI. Assessment of thyrotroph and corticotroph function, and thirst sensation, is necessary to diagnose and manage these disorders correctly. CSWS may be persistent in few patients and requires special attention to prescribe the appropriate care.
AB - Background: Patients with brain tumours have a high risk of water and electrolyte disorders (WED). Postsurgery diabetes insipidus (DI) may be transient or permanent, the syndrome of inappropriate antidiuretic hormone secretion (SIADH) and cerebral salt-wasting syndrome (CSWS) are usually transient. Methods: Retrospective study, including patients with suprasellar tumours, treated at Hôpital Necker, Institut Gustave-Roussy or Institut Curie, in Île-de-France, between 2007 and 2011. WED were noted if they persisted >1 month after surgery. Results: 159 patients were included, 54.1% girls, 43.9% boys. Tumour types were: glioma (43.4%), craniopharyngioma (43.4%), germinoma (11.3%), others (1.9%). Age at diagnosis was 7.1 ± 4.6 years. The median time from end of treatment was 1.9 (0-7.8) years. DI was the most frequent disorder after tumour treatment (50.3%) and was significantly associated with surgery (p < 0.001). Persistent CSWS was present in 3.6%, persistent SIADH in 1.3%. Two cases of hypernatraemia were due to adipsia. Thyrotropin deficiency after treatment was noted in 68.9% of patients tested, adrenocorticotropin deficiency in 66.2%. Conclusions: Patients with suprasellar tumours have a high incidence of long-term WED, mainly DI. Assessment of thyrotroph and corticotroph function, and thirst sensation, is necessary to diagnose and manage these disorders correctly. CSWS may be persistent in few patients and requires special attention to prescribe the appropriate care.
KW - Cerebral salt-wasting syndrome
KW - Diabetes insipidus
KW - Electrolyte disorders
KW - Hyponatraemia
KW - Suprasellar tumours
UR - http://www.scopus.com/inward/record.url?scp=84921433197&partnerID=8YFLogxK
U2 - 10.1159/000368401
DO - 10.1159/000368401
M3 - Article
C2 - 25377653
AN - SCOPUS:84921433197
SN - 1663-2818
VL - 82
SP - 364
EP - 371
JO - Hormone Research in Paediatrics
JF - Hormone Research in Paediatrics
IS - 6
ER -